WT1 and focal segmental glomerulosclerosis: Wilms’ tumor 1 (WT-1), a urinary exosomal biomarker with apparent podocyte specificity, is another promising noninvasive biomarker that can detect early progression and treatment-induced regression of podocyte injury in FSGS or steroid-sensitive nephrotic syndrome.